Clinical Trials Logo
  1. Home
  2. Antiphospholipid Syndrome
  3. NCT01538134

Antiphospholipid Antibodies and Fetal Growth Restriction

Antiphospholipid Syndrome Clinical Trial

Official title:
Antiphospholipid Antibodies and Early Fetal Growth Restriction (<34 Weeks of Gestation). A Case Control Study.

Clinical Trial Summary

The Antiphospholipid Syndrome is an immune disease where the presence of antibodies directed against cell membrane phospholipids (antiphospholipid antibodies) can cause an hypercoagulable state that causes thrombosis and obstetric complications (miscarriages, stillbirths). Since 1999 the Sapporo Criteria for Antiphospholipid Syndrome diagnosis includes the development of fetal growth restriction (diagnosed postpartum), but this was done without solid evidence of a relation between the two or using the most common form of fetal growth restriction diagnosis (ultrasound). Our study will try to add information to this particular point.

Clinical Trial Description

n/a

Study Design

Observational Model: Case Control, Time Perspective: Prospective

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT01538134
Study type Observational
Source Saint Thomas Hospital, Panama
Contact
Status Not yet recruiting
Phase N/A
Start date June 2015
Completion date March 2016
View Details
See also
  Status Clinical Trial Phase
Completed NCT01475149 - Effect of HCQ on AnxA5 Resistance Assay in Antiphospholipid (aPL) Positive Patients With and Without Systemic Lupus Erythematosus (SLE) N/A
Completed NCT00537290 - A Pilot Study of Rituximab for the Anticoagulation Resistant Manifestations of Antiphospholipid Syndrome Phase 2
Recruiting NCT00616317 - Register for Pediatric Patients With Antiphospholipid Syndrome (APS): European Project Extended Internationally Study
Recruiting NCT00198068 - Predictors of Pregnancy Outcome in Systemic Lupus Erythematosus (SLE) and Antiphospholipid Syndrome (APS)
Completed NCT00180817 - Longitudinal Study of the Clinical and Haematological Cause of Women With Antiphospholipid Antibodies.
Completed NCT03682419 - Evaluation of Precision and Accuracy of INR Measurements in a Point of Care Device (OPTIMAL) N/A
Not yet recruiting NCT03303508 - Measurement of Anti-dsDNA by Both CLIFT & ELISA N/A
Recruiting NCT04262492 - International Registry of Thrombotic APS Patients Treated With Direct Oral Anticoagulants
Withdrawn NCT00180778 - Steroids and Antiphospholipid Syndrome- Related Pregnancy Loss Phase 1/Phase 2
Enrolling by invitation NCT05583305 - Prevalence and Etiologies of Intracranial Stenosis in Patients With Antiphospholipid Syndrome
Recruiting NCT05644210 - Telitacicept Followed With Rituximab Therapy on APS Secondary to SLE
Recruiting NCT02303171 - Use of Warfarin After the First Trimester in Pregnant Women With APS Phase 4
Not yet recruiting NCT06420154 - The Safety and Efficacy of Anti-CD19 CAR-T Cells in Patients With Relapsed/Refractory Autoimmune Diseases Early Phase 1
Completed NCT00674297 - Effects of Fluvastatin on Proinflammatory and Prothrombotic Markers in Antiphospholipid Syndrome Patients Phase 2
Recruiting NCT05859997 - Universal CAR-T Cells (BRL-301) in Relapse or Refractory Autoimmune Diseases N/A
Recruiting NCT06373003 - Negative Antiphospholipid Syndrome: a Multicentric Study
Recruiting NCT06373926 - Evaluation of Cell Membrane Expression of Annexin A2 on Monocytes by Flow Cytometry in Primary Antiphospholipid Syndrome N/A
Recruiting NCT01818505 - The Influence of Antiphospholipid Antibodies on the Relationship Between Hyperurecemia, Gout and Metabolic Syndrome N/A
Completed NCT00878137 - Reliability of Point-of-care INR Measurements in Patients With Antiphospholipid-antibody Syndrome Treated With Warfarin N/A
Completed NCT01104337 - Drug Interaction Between Paracetamol and Warfarin Phase 4